Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 1, 2024

https://www.prnewswire.com/news-releases/poseida-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-302104558.html

SAN DIEGO, April 1, 2024 /PRNewswire/ — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Compensation Committee of its Board of Directors granted an inducement award to Syed Rizvi, M.D., the Company’s new Chief Medical Officer. This grant is made pursuant to the Company’s 2022 Inducement Plan as an inducement material to Dr. Rizvi entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.